Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039337 | 0.84 | PDK1 (0.48) | CHRM3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2395603 | 0.83 | CCR5 (0.41) | OPRD1OPRM1CCR5CHRM3SLC6A2 | |
| Hydrochloric Acid SCHEMBL2396854 | 0.82 | OPRM1 (0.41) | OPRD1OPRM1CCR5CHRM3SLC6A2 | |
| SCHEMBL1937237 | 0.81 | HTR4 (0.43) | OPRM1ACHECCR5CHRM3SLC6A2 | |
| SCHEMBL2393607 | 0.81 | PGR (0.43) | OPRM1ACHECCR5CHRM3 | |
| SCHEMBL2541058 | 0.79 | CCR5 (0.41) | OPRM1ACHECCR5CHRM3SLC6A2 | |
| SCHEMBL3364749 | 0.79 | ACHE (0.43) | OPRM1ACHECCR5 | |
| SCHEMBL2397352 | 0.78 | OPRK1 (0.42) | OPRD1OPRM1CCR5CHRM3SLC6A2 | |
| Trifluoroacetic Acid SCHEMBL3029533 | 0.78 | TACR1 (0.46) | OPRD1ACHECHRM3SLC6A2SLC6A4 | |
| SCHEMBL3757785 | 0.76 | OPRM1 (0.69) | OPRD1OPRM1ACHECCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204275-A1 | N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-08-12 | — | — | US | claimed |
| US-20100204275-A1 | N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204275-A1 | N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | OPRD1 125/4885OPRM1 55/4885ACHE 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.